KLK3 and prostate carcinoma: The alpha-blockers cause dizziness, headache, weakness, asthenia, retrograde ejaculation, and nasal congestion, while the 5-alpha reductase inhibitors cause ejaculatory dysfunction, erectile dysfunction, gynecomastia, and also lower PSA by 50% after 6 months of therapy which affect prostate cancer diagnosis (18-20).